FDA, Health Canada approve Polish moly

The U.S. Food and Drug Administration (FDA) and Health Canada have approved the use of the Maria Research Reactor (Maria) in Poland as a site to irradiate highly enriched uranium targets for molybdenum-99 (Mo-99) production, according to healthcare technology firm Covidien of Dublin, Ireland.

Covidien will use the Mo-99 from Maria to manufacture technetium-99m (Tc-99m). Patients should begin to benefit from Maria-produced Mo-99 in the U.S. and Canada later this month, the company said.

Related Reading

Covidien signs deal to produce Mo-99 at Polish reactor, February 17, 2010

Covidien to halt generator production, January 22, 2010

Covidien pharmaceutical sales dip in fiscal Q1, January 20, 2010

Covidien to sell radiopharmacy business, December 17, 2009

Covidien shows mixed results in Q4, fiscal 2009, November 20, 2009

Copyright © 2010 AuntMinnie.com

Page 1 of 435
Next Page